Eberhard Rabe1, Hugo Partsch2, Nick Morrison3, Mark H Meissner4, Giovanni Mosti5, Christopher R Lattimer6, Patrick H Carpentier7, Sylvain Gaillard8, Michael Jünger9, Tomasz Urbanek10, Juerg Hafner11, Malay Patel12, Stephanie Wu13, Joseph Caprini14, Fedor Lurie15, Tobias Hirsch16. 1. Department of Dermatology, University of Bonn, Bonn, Germany. 2. Department of Dermatology, Medical University of Vienna, Vienna, Austria. 3. Center for Vein Restoration, Mesa, AZ, USA. 4. Department of Surgery, Harborview Medical Center, Seattle, WA, USA. 5. Angiology Department, Clinica MD Barbantini, Lucca, Italy. 6. Josef Pflug Vascular Laboratory, West London Vascular and Interventional Centre, Ealing Hospital & Imperial College, London, UK. 7. Centre de Recherche Universitaire de La Léchère, Equipe THEMAS, Université Joseph Fourier, Grenoble, France. 8. SIGVARIS Management AG, Winterthur, Switzerland. 9. Department of Dermatology, University of Greifswald, Greifswald, Germany. 10. Department of General Surgery, Vascular Surgery, Angiology and Phlebology, Medical University of Silesia, Katowice, Poland. 11. Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. 12. First Choice Vascular, Swastik Society, Ahmedabad, India. 13. Department of Podiatric Surgery & Applied Biomechanics, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA. 14. Department of Vascular Surgery, The University of Chicago, Chicago, IL, USA. 15. Department of Vascular Surgery, University of Michigan, Ann Arbor, MI, USA. 16. Practice for Internal Medicine and Vascular Diseases, Halle, Germany.
Abstract
OBJECTIVES: Medical compression therapy is used for non-invasive treatment of venous and lymphatic diseases. Medical compression therapy-associated adverse events and contraindications have been reported, although some contraindications are theoretically based. This consensus statement provides recommendations on medical compression therapy risks and contraindications. METHODS: A systematic literature search of medical compression therapy publications reporting adverse events up until November 2017 was performed. A consensus panel comprising 15 international experts critically reviewed the publications and formulated the recommendations. RESULTS: Sixty-two publications reporting medical compression therapy adverse events were identified. The consensus panel issued 21 recommendations on medical compression therapy contraindications and adverse event risk mitigation, in addition to reviewing medical compression therapy use in borderline indications. The most frequently reported non-severe medical compression therapy-associated adverse events included skin irritation, discomfort and pain. Very rare but severe adverse events, including soft tissue and nerve injury, were also identified. CONCLUSION: This consensus statement summarises published medical compression therapy-associated adverse events and contraindications, and provides guidance on medical compression therapy. Severe medical compression therapy-associated adverse events are very rarely encountered if compression is used correctly and contraindications are considered.
OBJECTIVES: Medical compression therapy is used for non-invasive treatment of venous and lymphatic diseases. Medical compression therapy-associated adverse events and contraindications have been reported, although some contraindications are theoretically based. This consensus statement provides recommendations on medical compression therapy risks and contraindications. METHODS: A systematic literature search of medical compression therapy publications reporting adverse events up until November 2017 was performed. A consensus panel comprising 15 international experts critically reviewed the publications and formulated the recommendations. RESULTS: Sixty-two publications reporting medical compression therapy adverse events were identified. The consensus panel issued 21 recommendations on medical compression therapy contraindications and adverse event risk mitigation, in addition to reviewing medical compression therapy use in borderline indications. The most frequently reported non-severe medical compression therapy-associated adverse events included skin irritation, discomfort and pain. Very rare but severe adverse events, including soft tissue and nerve injury, were also identified. CONCLUSION: This consensus statement summarises published medical compression therapy-associated adverse events and contraindications, and provides guidance on medical compression therapy. Severe medical compression therapy-associated adverse events are very rarely encountered if compression is used correctly and contraindications are considered.
Authors: Paula S Azevedo; Bertha F Polegato; Marcos F Minicucci; Sergio A R Paiva; Leonardo A M Zornoff Journal: Arq Bras Cardiol Date: 2015-12-08 Impact factor: 2.000
Authors: María Nieves Muñoz-Alcaraz; Antonio José Jiménez-Vílchez; Mirian Santamaría-Peláez; Luis A Pérula-de Torres; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Presentación Jorge-Gutiérrez; Jesús Serrano-Merino; Esperanza Romero-Rodríguez; Lorena Rodríguez-Elena; Raquel Refusta-Ainaga; María Pilar Lahoz-Sánchez; Belén Miró-Palacios; Mayra Medrano-Cid; Rosa Magallón-Botaya; Luis A Mínguez-Mínguez; Josefa González-Santos; Jerónimo J González-Bernal Journal: J Clin Med Date: 2022-04-16 Impact factor: 4.964
Authors: María Nieves Muñoz-Alcaraz; Luis A Pérula-de Torres; Antonio José Jiménez-Vílchez; Paula Rodríguez-Fernández; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Presentación Jorge-Gutiérrez; Jesús Serrano-Merino; Esperanza Romero-Rodríguez; Lorena Rodríguez-Elena; Raquel Refusta-Ainaga; María Pilar Lahoz-Sánchez; Belén Miró-Palacios; Mayra Medrano-Cid; Rosa Magallón-Botaya; Mirian Santamaría-Peláez; Luis A Mínguez-Mínguez; Jerónimo J González-Bernal Journal: J Clin Med Date: 2022-03-28 Impact factor: 4.241